Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Atea Pharmaceuticals (AVIR) Receivables - Other (2020)

Atea Pharmaceuticals' Receivables - Other history spans 1 years, with the latest figure at $5.8 million for Q4 2020.

  • Quarterly Receivables - Other changed N/A to $5.8 million in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $5.8 million through Dec 2020, changed N/A year-over-year, with the annual reading at $5.8 million for FY2020, N/A changed from the prior year.
  • Receivables - Other came in at $5.8 million for Q4 2020.
  • In the past five years, Receivables - Other ranged from a high of $5.8 million in Q4 2020 to a low of $5.8 million in Q4 2020.